FDA-Approved Drugs

The following drugs have been approved since the year 2000 for the treatment of non-Hodgkin's lymphoma:

Treanda (bendamustine)

FDA approved October 2008

Bendamustine is a chemotherapy drug approved for the treatment of B-cell non-Hodgkin lymphomas.

Arranon (nelarabine)

FDA approved October 2005

This chemotherapy drug is approved for the treatment of T-cell lymphoblastic lymphoma.

Bexxar (tositumomab)

FDA approved June 2003

This drug is a monoclonal antibody that targets specific lymphoma cells. Tositumomab is linked to a radioactive agent called iodine-131 (I-131). The medicine allows radiation to be delivered directly to the sites of the lymphoma.

Zevalin (ibritumomab tiuxetan)

FDA approved February 2002

This drug is a protein that targets specific lymphoma cells. To be effective ibritumomab tiuxetan is linked to a radioactive agent called yttrium chloride (Y-90). The medicine allows radiation to be delivered directly to the sites of the lymphoma.